Browse articles on EyeWorld.org from the Cornea section. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
There are several companies in the field of artificial irises. Kevin M. Miller, MD, and Sathish Srinivasan, MD, discussed the available products and important considerations when working with artificial irises.
With the COVID-19 pandemic temporarily closing practices around the country, many ophthalmologists had to figure out how to still communicate with and treat their patients. Several physicians commented on how the pandemic has affected their dry eye patient population and trends they have seen.
A retrospective study based on insurance claims data is giving real-world insights into prescribing/treatment patterns for two dry eye medications—cyclosporine ophthalmic emulsion (Restasis, Allergan) and lifitegrast ophthalmic solution (Xiidra, Novartis).1 In doing so, researchers can make inferences on adherence, discontinuation, and more.
When teens come into the clinic, it’s important to consider that they might have dry eye or meibomian gland disease. Investigators in a recent study found that among minors coming in for eye exams, 15% were experiencing dry eye discomfort and 9% had signs of meibomian gland dropout, according to lead investigator Anna Tichenor, PhD.1
The COVID-19 pandemic has affected all areas of medicine, including eye banking. While much more is known about SARS-CoV-2 and the illness it causes, there are still several unknowns that continue to be investigated as they pertain to the safety of donor tissue.
Get the latest ophthalmology news delivered to your inbox every Friday.